data stringlengths 155 7.37k | criteria stringlengths 30 16.5k | __index_level_0__ int64 0 38.5k |
|---|---|---|
Study Objectives
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations:
1. Pediatric patients with congenital hyperinsulinism
2. Pediatric patients with neuroblastoma
3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumor
4. Adult patie... | Inclusion Criteria:
* 1. Pediatric patients (less than 17 years old) with congenital hyperinsulinism
* 2. Pediatric patients (less than 17 years old) with neuroblastoma
* 3. Pediatric patients (less than 17 years old) or Adult patients (17 or older) with known or clinically suspected neuroendocrine tumor outside of th... | 28,772 |
Study Objectives
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estradiol by the tumor cells. So... | Inclusion Criteria:
* Histologically or cytologically confirmed breast cancer
* Metastatic disease
* Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:
* Lesion >= 10 mm on CT scan (5 mm sections)
* Lesion >= 20 mm on CT scan or MRI (10 mm sections)
* Bone di... | 26,402 |
Study Objectives
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
Conditions: Relapsed Small Cell Lung Cancer
Intervention / Treatment:
DRUG: CS1001
Location: China
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE1
Primary Pur... | Inclusion Criteria:
* Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and experienced progression since first-line standard platinum containing dual-drug chemotherapy.
* Patients whose initial diagnosis was limited must undergo radical chest radiotherapy and the time of tumor progression is ... | 23,273 |
Study Objectives
Waldenström's Macroglobulinemia (lymphoplasmacytic lymphoma, WM) remains incurable with limited therapeutic options and notably absent FDA approved therapy with any WM indication. Therefore, there is a need to identify new therapeutic agents for WM patients both in the upfront and relapsed/refractory s... | Inclusion Criteria:
* 18 years of age or older
* Must have received prior therapy for their WM and have relapsed or refractory WM. Any number of prior therapies is acceptable
* Measurable disease, defined as presence of immunoglobulin M paraprotein with a minimum IgM level of equal to or greater than 2 times the ULN a... | 34,383 |
Study Objectives
The present study is a multicenter, prospective phase II-study investigating the combination of treosulfan, etoposide, and cyclophosphamide as conditioning regimen for patients with acute lymphoblastic leukemia who are not eligible for a TBI-containing regimen.
Conditions: Acute Lymphoblastic Leukemia... | Inclusion Criteria:
* Acute lymphoblastic leukemia in first or subsequent complete remission
* Indication for allogeneic stem cell transplantation according to the actual protocol of the German Acute Lymphoblastic Leukemia Study Group
* Patient's age: 18-65 years
* HLA-identical or compatible related or unrelated dono... | 32,153 |
Study Objectives
The molecular mechanisms involved in squamous cell carcinoma of the anus (SCCA) are poorly elucidated. HIV-positive and renal transplant patients are at high risk for developing SCCA, indicating that immune suppression plays a facilitating role. The investigators previously demonstrated that chromosoma... | Inclusion Criteria:
* Biopsy proven Squamous cell carcinoma of the anus
* Informed consent
Exclusion Criteria:
* None | 9,577 |
Study Objectives
The purpose of this study is to evaluate the safety and tolerability as well as the pharmacodynamic effects of multiple doses of AVX-470 administered orally in patients with active ulcerative colitis.
Conditions: Ulcerative Colitis
Intervention / Treatment:
DRUG: AVX 470, DRUG: Placebo
Location: Can... | Inclusion Criteria:
* Men or women aged 18 75, inclusive
* Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal segments of bowel
* Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥ 2 and > 15 cm of involvement beyond the anal verge
Exclusion Criteri... | 30,992 |
Study Objectives
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. The study is conducted at locations within and outside of the United States. Testing is performed on urine specimen... | Inclusion Criteria:
* Subject is ≥ 40 years of age
* Subject has provided documented informed consent as required by the reviewing IRB or EC. Experimental Bill of Rights will be documented for all subjects enrolled in applicable states.
* Subject is considered disease positive within 12 months (365 days) of enrollment... | 5,787 |
Study Objectives
This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at... | Inclusion Criteria:
* Male and Female subjects 18 years of age and older
* Have a primary diagnosis, or a high clinical suspicion, of cancer in the lung warranting surgery based on CT/PET or other imaging
* Are scheduled to undergo surgical thoracoscopy for diagnostic wedge resection followed by anatomic lung resectio... | 23,045 |
Study Objectives
The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants... | Inclusion Criteria:
* For Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor.
* For Phase 1a and 1b, prior PD-1 or PD-L1 therapy or other immunotherapy is allowed, if the following criteria are met:
* Must not have experienced a toxicity that led to permanent disc... | 24,056 |
Study Objectives
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream. This circulating tumor DNA (ctDNA) can be detected by very sensitive, specialized laboratory tests. Measurement of ctDNA has been ... | Inclusion Criteria: .
* 18 years of age or older who are scheduled to undergo a screening or diagnostic colonoscopy by Dr. Phillip Fleshner
Exclusion Criteria:
* Prior history of cancer excluding basal cell carcinoma of the skin | 24,711 |
Study Objectives
Screening programs and advances in imaging have led to more breast lesions being diagnosed at an impalpable stage. Multiple localisation techniques for nonpalpable breast lesions have been developed during the past decades. Specifically, several alternatives to the golden standard hooked-wire technique... | Inclusion Criteria:
* Breast conserving surgery with preoperative localisation
* Minimum 18 years old | 36,783 |
Study Objectives
This is a two part phase I study in Japanese patients that will determine the safety, tolerability and pharmacokinetics of pazopanib monotherapy and of pazopanib in combination with lapatinib.
Conditions: Carcinoma, Renal Cell
Intervention / Treatment:
DRUG: pazopanib, DRUG: Lapatinib
Location: Japa... | Inclusion criteria:
* Signed informed consent.
* Histologically or cytologically confirmed diagnosis of advanced solid tumor.
* Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study.
* ECOG performance status of 0 or 1.
* Adequate bone marrow res... | 1,060 |
Study Objectives
* The recently introduced chemoembolization has been considered to be a very attractive new method in terms of response in the treatment of liver metastases from colon cancer carcinoma (LM-CRC). It appears to be particularly useful if carried out with the new embolization materials.
* An 80% response r... | Inclusion Criteria:
* Unresectable hepatic metastases from colorectal carcinoma (CRC-LM)
* Progression of disease after first line therapy containing Irinotecan completed at least one month previously
* Performance status (PS) 0-2
* Biochemistry parameters within normal limits (ALT and gamma glutamyl transpeptidase no... | 22,451 |
Study Objectives
Central South University in collaboration with Tianjin University developed the first domestically produced Chinese minimally invasive surgical (MIS) robot system which named "Micro Hand S" in 2013. This new MIS robot had been authorized to enter the clinical trial stage by the Ethics Committee of the ... | Inclusion Criteria:
* histologically confirmed rectal cancer; ASA score < 3
Exclusion Criteria:
* palliative resections, combined resections, distant metastasis, a previous history of abdominal/or pelvic surgery | 27,381 |
Study Objectives
This phase I trial studies the side effects and best way of giving trastuzumab emtansine in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread to other parts of the body or nearby tissue and cannot be removed by surgery. Biological therapies, s... | Inclusion Criteria:
* Signed study-specific informed consent form
* Histologically or cytologically documented breast cancer
* Metastatic or unresectable locally advanced/recurrent breast cancer
* HER2-positive disease documented as in situ hybridization (ISH)-positive and/or 3+ by immunohistochemistry (IHC) on previo... | 6,956 |
Study Objectives
The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is.
This new therapy consists of an immunotherapy, that is an approach focusing on the immune system, and it targets ALL patients in complete remission but who may still have th... | Inclusion Criteria:
* Adult subjects with Ph+ ALL in CHR (1st or 2nd) with MRD positivity confirmed at baseline, older or equal to 60 years or not eligible for other post-CHR treatment modalities.
* WHO score 0-1.
* Hematopoietic, liver and renal normal functions defined as follows:
WBC bigger or equal to 2.000/mm3 l... | 18,195 |
Study Objectives
the efficacy and safety ofhe use of regorafenib in combination with nivolumab
Conditions: Advanced and Metastatic Solid Tumor
Intervention / Treatment:
DRUG: Regorafenib, DRUG: Nivolumab
Location: Japan
Study Design and Phases
Study Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Primary Purpose: TREATM... | Inclusion Criteria:
* Patients who provided written informed consent to be subjects in this trial
* Patients at least 20 years of age on the day of providing consent
* Dose-escalation cohort: Patients with histologically or cytologically confirmed advanced or metastatic solid tumors.
Expansion cohort: Patients wit... | 33,798 |
Study Objectives
The purpose of this study is to determine the safety of regorafenib, an antiangiogenic drug, when combined with radioembolization using SIR-Spheres® microspheres in the treatment of colorectal cancer (CRC) that has spread to the liver.
Conditions: Colorectal Neoplasms
Intervention / Treatment:
DEVICE... | Inclusion Criteria:
* Histologically confirmed metastatic adenocarcinoma of the colon or rectum.
* Patients who have been previously treated with or are not candidates for fluorouracil, oxaliplatin, irinotecan, and if Kras wild-type, anti EGFR therapy.
* Considered an appropriate candidate for regorafenib therapy.
* M... | 37,210 |
Study Objectives
This study aims to investigate the significance of minimal residual axillary disease following NAC, with a particular focus on micrometastases (ypNmi), in comparison to pathologic lymph node-negative (ypN0) or macrometastases (ypN+). The investigators will further explore the prognostic implications of... | Inclusion Criteria:
* Stage II or III primary breast cancer patients
* Patients who performed neoadjuvant chemotherpay
* Patients who underwent axillary lymph node dissection with or without sentinel lymph node biopsy
Exclusion Criteria:
* Patients who performed upfront surgery
* De novo stage IV patients | 16,221 |
Study Objectives
This clinical trial is being conducted to assess whether second forward view examination of proximal colon could increase adenoma detection rate of right colon.
Conditions: Colon Adenoma
Intervention / Treatment:
PROCEDURE: Second Examination
Location: China
Study Design and Phases
Study Type: INTE... | Inclusion Criteria:
* all patients undergoing colonoscopy for screening in our hospital
Exclusion Criteria:
* previous history of resection of colon;
* familial polyposis syndrome
* inflammatory bowel disease
* active antiplatelet or anticoagulant therapy prevent polypectomy;
* pregnancy or lactating women | 6,662 |
Study Objectives
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality will have associated breast cancer at surgical removal of the area.
Condit... | Inclusion Criteria:
* Women 20 years of age or older
* Imaging abnormality necessitating a core needle biopsy
* Core needle biopsy revealing ALH or LCIS
* Patients may have a history of fibroadenoma and/or proliferative breast lesions with atypia
Exclusion Criteria:
* History and/or concomitant diagnosis of invasive... | 29,131 |
Study Objectives
Liposomal formulations are frequently used today in the treatment of cancer. LiPlaCis is the first targeted liposomal formulation with a tumour triggered release mechanism to undergo clinical development in oncology and it is expected that LiPlaCis will improve the therapeutic index of cisplatin compar... | Inclusion Criteria:
* Histological or cytological documented locally advanced or metastatic solid tumour relapsed on 2 or more different prior therapies. From step 5 and extension phase, population limited to Skin Cancer patients (non screened) or metastatic Breast Cancer patients or metastatic castration-resistant pr... | 30,142 |
Study Objectives
This study will evaluate the impact of a whole-of-community multi-level adaptive systems intervention on implementation of community change and youth population physical activity. Building on local health department partnerships, the investigators will conduct a two-wave staggered-start community rando... | Inclusion Criteria:
* Community located in rural micropolitan area
* Community is a one high school town
* Organization is a school district
* Organization is a after school program
* Organization is a youth club system
* Organization is a youth sport delivery system
* Leaders of settings in school, after-school, club... | 13,988 |
Study Objectives
The objective of our study is to determine which factors affect willingness to participate in gynecologic oncology clinical trials. Women with a diagnosis of gynecologic malignancy will be approached to complete a survey assessing willingness to participate in clinical trials. The validated Attitudes a... | Inclusion Criteria:
* Diagnosis of gynecologic malignancy
* English or Spanish literate
Exclusion Criteria:
* Prior enrollment in a clinical trial
* Currently pregnant
* Currently incarcerated | 23,812 |
Study Objectives
The investigators aimed to research the incidence of hyperlactatemia in craniotomy cases, the relationship of lactate elevation with tumor type and other factors that may be related, and whether the general anesthesia method applied (inhalation anesthesia or total ıntravenous anesthesia) affects lactat... | Inclusion Criteria:
* Scheduled to undergo elective craniotomy for an intracranial mass
* adult patients
Exclusion Criteria:
* emergency
* In situations that may cause hyperlactatemia (such as sepsis, hepatic or renal failure, shock state, or patients who need inotropic support) | 13,370 |
Study Objectives
Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma
Conditions: Multiple Myeloma
Intervention / Treatment:
DRUG: Thalidomide, DRUG: Biphosphonates
Location: France
Study Design and Phases
Study Type: INTERVENT... | Inclusion Criteria:
* de novo myeloma
* according to Durie and Salmon classification stage II, III and stage I with a lytic bone lesion
* patients from 18 to 65 years old
* beta2microglobulin < 3 mg/l or del13 absent
* signed informed consent
* eligible for transplantation
Exclusion Criteria:
* peripheral neurologic... | 37,621 |
Study Objectives
This protocol corresponds to a prospective, multicentre, open label, phase II study designed to evaluate the efficacy of CPX-351 in elderly patients with secondary or high-risk AML. The clinical trial is divided into pre-treatment, treatment (induction and consolidation cycles) and follow-up periods an... | Inclusion Criteria:
* Written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure. Informed consent form must be signed by the patient and the investigator.
* Age 60 to 75 years at the time of diagnosis of A... | 8,761 |
Study Objectives
Determine the safety and efficacy of novel suture in esophageal anastomosis. Specific Aims: 1) Determine the safety of using STRATAFIX suture in esophagogastric anastomosis by measuring anastomotic leak rate; and 2) Determine efficacy of STRATAFIX suture in esophagogastric anastomosis by measure anasto... | Inclusion Criteria:
* All patients with esophageal cancer who are deemed candidates for minimally invasive robot assisted Ivor Lewis esophagogastrostomy.
* Patients who provide written informed consent for the study.
Exclusion Criteria:
* Any patient with esophageal cancer who is not deemed a surgical candidate or w... | 8,132 |
Study Objectives
A First-in-human, dose-escalation, dose-expansion phase I clinical study of JS004 in subjects with recurrent/refractory malignant lymphoma in China, to evaluate the safety, tolerbility, PK, immunogenicity,antitumor activity and biomarkers of JS004, to define MTD and RP2D of JS004. A cycle is 21 days(3 ... | Inclusion Criteria:
*Able to understand and sign informed consent voluntarily
*18-70 years old
*Pathologically confirmed malignant lymphoma
*ECOG PS: 0-1
*Expected survival ≥12 weeks
*At least one measurable lesion per Lugano response critieria 2014 for Lymphoma
*Adequate organ and marrow function, as defined be... | 3,588 |
Study Objectives
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone.
2. Verify pre-built EGFR mutation prediction model for NSCLC brain metastases
Conditions: Multiple B... | Inclusion Criteria:
* 18 years of age or older;
* the pathological diagnosis of non-small cell lung cancer and detection of pulmonary primary ARMs / sequencing EGFR mutation;
* enhanced MRI showed brain metastases ≥ 2 or NSCLC of brain metastases after resection of residual lesions in ≥ 2 / intracranial metastases in ... | 19,415 |
Study Objectives
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Conditions: ... | Inclusion criteria :
* Cancer patients greater than 18 years of age who have completed all assessments required to meet the primary objectives of a parental phase 1, 2 or 3 clinical study of iniparib as monotherapy or in a combination regimen.
* Previously received and are continuing to derive clinical benefit from in... | 37,229 |
Study Objectives
The purpose of this study is to determine whether cessation of hormone replacement therapy for one or two months before a screening mammogram will improve its performance by decreasing breast density.
Conditions: Breast Cancer
Intervention / Treatment:
OTHER: temporary discontinuation of hormone ther... | Inclusion Criteria:
* 1 or more prior screening mammograms at Group Health Cooperative within the past 2 years
* Currently taking HRT
* Taking HRT at prior screening mammogram
* Due for a screening mammogram
Exclusion Criteria:
* BI-RADS breast density of 1 (entirely fat)
* Previous cardiovascular events (heart surg... | 9,149 |
Study Objectives
This is a randomised, double-blind, cross-over study of pazopanib versus sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) who have received no prior systemic therapy for advanced or metastatic RCC. Approximately 160 eligible patients will be stratified based on the ... | Inclusion Criteria:
* Patients must provide written informed consent prior to performance of any study-specific procedures or assessments and must be willing to comply with treatment and follow up. Procedures conducted as part of the patient's routine clinical management (e.g. blood count, imaging study) and obtained ... | 17,442 |
Study Objectives
Fatigue is frequently identified as one of the most troublesome symptoms in cancer patients and there are very few conventional therapies which can address the symptom of fatigue in patients who are undergoing cancer treatment.
This study will be testing whether the administration of a complementary t... | Inclusion Criteria:
* Diagnosed with any type of cancer. Patient may have newly diagnosed, relapsed or a second malignant disease.
* Receiving any type of cytotoxic chemotherapy with 6 or more cycles post study enrollment administered intermittently every two or three weeks with no planned radiation treatment.
* Is ex... | 1,937 |
Study Objectives
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy with radiosurgery for locally advanced pancreas cancer.
Conditions: Pancreatic Cancer
Intervention / Treatment:
DEVICE: Stereotactic Radiosurgery (Cyberknife)
Location: United States
Study Design and Phases... | Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.
* Histologically confirmed malignancies of the pancreas, (ampulla of Vater or periampullary duodenum, tumors may be included when the head of pancreas is secondarily involved and unresectable criteria are met).
* Unresectable by CT criteria or unresectable a... | 30,943 |
Study Objectives
The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied.
Abraxane is designed to block cancer cells from dividing, which may cause them to die.
Conditions: Colorectal Cancer, Cancer of Gast... | Inclusion Criteria:
* Patient must have histologically or cytologically confirmed colorectal adenocarcinoma or small bowel adenocarcinoma
* Metastatic disease documented on diagnostic imaging studies with measurable disease per RECIST version 1.1.
* Refractory disease defined as: a) prior treatment with fluoropyrimidi... | 9,125 |
Study Objectives
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast cancer. Hydroxychloroquine is a substance that decreases immune responses in th... | Inclusion Criteria:
* Signed written informed consent
* Diagnosis of estrogen positive breast cancer, estrogen receptor-positive and HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Postmen... | 549 |
Study Objectives
This phase I trial studies the side effects and the best dose of nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the cancer-testes antigen NY-ESO-1 gene AND have spread from where it started to nearby tissue or lymph nodes... | Inclusion Criteria:
* Stage IV or locally advanced histologically confirmed solid tumors for which no alternative therapies with proven survival advantage are available
* At least 1 lesion amenable for outpatient biopsies; this should be a cutaneous or palpable metastatic site or a deeper site accessible by image-guid... | 1,974 |
Study Objectives
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients
The objectives of this study are:
* To determine the safety and MTD of CPI-613 when ad... | Inclusion Criteria:
* Patients must have advanced and/or metastatic, histologically or cytologically documented solid tumors and lymphomas, for whom there is no available therapy shown to provide clinical benefit.
* Karnofsky Performance Status (KPS) of >70%.
* Must be ≥18 years of age.
* Expected survival >3 months.
... | 16,386 |
Study Objectives
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab and everolimus, into the first-line multimodality therapy of glioblastoma. In the first portion of the treatment, bevacizumab will be added to standard concurrent radiation therapy plus temozolomide. After com... | Inclusion Criteria:
* Age >=18 years.
* Histologically confirmed intracranial glioblastoma multiforme (WHO grade 4).
* Patients who have had partial or complete surgical debulking are eligible, as are those with inoperable glioblastoma.
* No previous treatment with radiotherapy or systemic therapy. Local therapy with ... | 34,195 |
Study Objectives
The purpose of the study is to find out if the new drug sabatolimab when given in combination with azacitidine and venetoclax, is safe and has beneficial effects in participants with high or very high risk myelodysplastic syndrome (MDS) who are not suitable for treatment with intensive chemotherapy or ... | Inclusion Criteria:
* Signed informed consent must be obtained prior to participation in the study
* Age ≥ 18 years at the date of signing the informed consent form (ICF)
* Morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al, 2016) by local investigator a... | 12,678 |
Study Objectives
Combined with magnifying endoscopy,narrow-band imaging (NBI) contrasts microvascular architecture on lesion surface.The histology of early colorectal lesions could be predicted under NBI view.However,its capability for estimating invasion depth remains to be verified.The study is based on the hypothesi... | Inclusion Criteria:
* patients of early colorectal lesions with capillary pattern(CP) type II\&III,initially detected by white-light view and then examined by NBI with magnifying endoscopy.
Exclusion Criteria:
* lesions with CP type I;
* CP type III lesions with an obvious appearance of advanced cancer;
* lesions th... | 34,096 |
Study Objectives
According to the studies CC is successful at inducing ovulation in 50%-75% of cases, but only 30-40% becomes pregnant. The difference has been attributed to a negative action of clomifen citrate(CC) in the form of prolonged antiestrogenic effects on endometrial receptivity. For avoiding of these negati... | Inclusion Criteria:
* The patients with first treatment cycle
* Age between 25 and 30 years,
* Infertility for at least 2 years' duration,
* Oligomenorrhea or amenorrhea associated with a positive Progesterone challenge test
* Women with normal concentrations of prolactin, free thyroxin and thyroid-stimulating hormone... | 4,341 |
Study Objectives
In this clinical trial, the investigators want to know if cabazitaxel is more effective than methotrexate for patients with recurrent or metastatic squamous cell carcinoma of the head and neck in palliative treatment.
Conditions: Squamous Cell Carcinoma of the Head and Neck
Intervention / Treatment:
... | Inclusion Criteria:
* Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation.
* At least one measurable lesion by MRI or CT-scan according to RECIST 1.1.
* Progressive disease within 1 year after first line platinum-based c... | 9,000 |
Study Objectives
MicroRNAs (MiRNAs) regulate the translation of RNAs and are implicated in cell proliferation and renewal both under physiologically normal as well as in malignant conditions. Dysregulation of specific miRNAs may be associated with either gaining oncogenic or loosing tumor suppressing functions. MiRNA d... | Inclusion Criteria:
* Female,
* Breast Cancer
* > 18 years,
* regardless of histology, treatment phase, or stage
Exclusion Criteria:
* | 30,347 |
Study Objectives
This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metasta... | Inclusion Criteria:
* Aged ≥18 years at signing of informed consent.
* Histologically confirmed MBC, current stage IV.
* Documented HER2 overexpression or gene-amplified tumor immunohistochemistry 3+ or 2+, with confirmatory fluorescence in situ hybridization (FISH) +.
* Prior treatment with at least two (2) HER2-dire... | 5,915 |
Study Objectives
Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but can also reverse testo... | Inclusion Criteria:Overweight/obese women (BMI>27)
* Must have six or fewer menses /year or be amenorrheic
* Have either clinical or laboratory evidence of hyperandrogenism (hirsutism or elevated testosterone (T)) and /or PCOS ovary on ultrasound
Exclusion Criteria:
other uncorrected endocrinopathy- hyperprolactinem... | 32,553 |
Study Objectives
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular carcinoma (HCC)
Conditions: Hepatocellular Carcinoma
Intervention / Treatme... | Inclusion Criteria:
* The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
* Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.
* Barcelona clinic liver cancer-stage C
* Eastern Coopera... | 21,492 |
Study Objectives
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
Conditions: Prostate Cancer
Intervention / Treatment:
DRUG: GM-CSF
Location: United States
St... | Inclusion Criteria:
* Histologic diagnosis of adenocarcinoma of the prostate; stage T1-T3, N0-N1, M0
* Prior definitive therapy for primary prostate cancer consisting of:external beam radiotherapy;brachytherapy with or without pelvic external beam radiation; or radical prostatectomy with or without adjuvant or salvage... | 21,013 |
Study Objectives
The study was conducted based on randomized controlled experimental design with double-blind, pre-test-post-test to determine the effect of Reiki applied to pediatric oncology patients aged 5-7 years on pain, vital signs, oxygen saturation (SpO2) and quality of life. While the population of the study c... | Inclusion Criteria:
* Being treated in the pediatric oncology service at the time of the study
* Being between 5-7 years old
* Body temperature being within normal limits
* To have received at least 1 course of chemotherapy
* Absence of visual, auditory problems or mental retardation at a level that can fill the scale... | 37,665 |
Study Objectives
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
Conditions: Colorectal Cancer
Intervention / Treatment:
BIOLOGICAL: Ramucirumab, BIOLOGICAL: Placebo, DRUG: Irinotecan, DRUG: ... | Inclusion Criteria:
* Histologically or cytologically confirmed colorectal cancer, excluding primary tumors of appendiceal origin (participants are eligible to enroll irrespective of KRAS mutation status)
* Confirmed metastatic colorectal cancer (Stage IV)
* The participant has received first-line combination therapy ... | 2,273 |
Study Objectives
This was a multi-institutional, multinational, open-label, single-arm Phase Ib/II study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-MCC-DM1) administered by intravenous (IV) infusion in combination with pertuzumab in patients with ... | Inclusion Criteria:
* Histologically documented human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer.
* Tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory HER2 status testing and other exploratory assessments.
* Prior trastuzumab in... | 4,679 |
Study Objectives
Advanced biliary tract adenocarcinoma has a poor prognosis with limited therapeutic options. Nab-paclitaxel plus S-1 chemotherapy will be given to untreated patients with advanced biliary tract adenocarcinoma for the first-line treatment.
Conditions: Biliary Tract Cancer
Intervention / Treatment:
DRU... | Inclusion Criteria:
* Age, years: 18-70
* Histologically and cytologically confirmed advanced biliary tract adenocarcinoma, unresectable, measurable lesions according to RECIST criteria; ECOG score of 0-1; life expectancy ≥12 weeks;
* Untreated; more than 6 months after the last adjuvant chemotherapy (does not include... | 24,646 |
Study Objectives
Comparing the structural effects of TNFi and tocilizumab on the periarticular bone by performing a comprehensive analysis of the periarticular bone changes in RA patients treated with either TNFi or tocilizumab in a longitudinal Setting, using high-resolution peripheral quantitative computed tomography... | Inclusion Criteria:
* Females and males with RA erosions in the wrist and/or MCP joints
* Must be aged ≥ 18 years at time of consent
* Stable treatment with conventional DMARDs of at least 3 months
Exclusion Criteria:
* Patients exposed to abatacept or rituximab in the last 12 months
* Patients receiving glucocortic... | 20,301 |
Study Objectives
This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Healt... | Inclusion Criteria:
* Patients with confirmed diagnosis of clear-cell renal cell carcinoma
* Patients with evidence of metastatic disease
* Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
* Patients who received care at the selected medical centers, utiliz... | 4,645 |
Study Objectives
Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.
Conditions: Metastatic Melanoma
Inter... | Inclusion Criteria:
* 18 years or older
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix A)
* Metastatic melanoma eligible for {or currently on} standard of care CPI therapy (treating physician's choice) with measurable disease.
* Approximately 1 cm3 preferred but 1 mg minimum of accessi... | 27,752 |
Study Objectives
This is a research study for subjects who have been diagnosed with Adult T cell Leukemia/Lymphoma, a rare and aggressive peripheral T cell neoplasm caused by the virus HTLV1. Currently, there is no accepted standard therapy for this disease. The purpose of this research study is to evaluate the use of ... | Inclusion Criteria:
* Age ≥18 years at the time of signing the informed consent form.
* Able to adhere to the study visit schedule and other protocol requirements.
* Relapsed or refractory HTLV-1 associated Adult T-cell Leukemia/Lymphoma (Acute and lymphoma subtypes)
* All previous cancer therapy, including radiation,... | 31,803 |
Study Objectives
This is a multicenter, blinded prospective study of 2,000 women undergoing mammography for breast -related symptoms or signs. Breath tests will be performed in order to demonstrate that the outcome of mammography results combined with breast test results improves clinical sensitivity and specificity in... | Inclusion Criteria:
* Female aged 18 years or over
* Referred for mammography for a breast-related concern (e.g. breast mass, nipple discharge etc.)
* Understands the study, and is willing to give written informed consent to participate
* Approves collection of relevant additional data for clinical research record if ... | 8,612 |
Study Objectives
The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.
Conditions: Oncology, Solid Tumors... | Inclusion Criteria:
* Part A and Part FE (M3814 + avelumab): Participants must have histologically or cytologically proven advanced or metastatic solid tumors for which no standard therapy exists, standard therapy has failed, or participants are intolerant to or have rejected established therapy known to provide clini... | 14,682 |
Study Objectives
This is a randomized, open-label and parallel phase I study to compare pharmacokinetics (PK), pharmacodynamics (PD) and safety of goserelin acetate sustained-release microspheres for injection (LY01005) and ZOLADEX® following multiple administration in patients with prostate cancer.
Conditions: Prosta... | Inclusion Criteria:
* 18 years or older.
* Patients with locally advanced or metastatic prostate cancer suitable for endocrine therapy, including those who are suitable for endocrine therapy (such as patients with biochemical recurrence after adjuvant endocrine therapy and radical therapy) following radical therapy.
*... | 17,395 |
Study Objectives
Early detection of lung cancer and early removal of the cancer nodules facilitates the diagnosis and treatment. However, not all nodules are malignant. Currently the standard method to diagnose lung cancer is to remove any suspicious nodules from the lung in a surgical procedure.
This study is being c... | Inclusion Criteria:
* Subjects with 0.8-3 cm solitary pulmonary nodules with high probability for malignancy
* Candidate is scheduled to undergo lung biopsy procedure to determine clinical diagnosis, such as Bronchoscope biopsy, Electromagnetic Navigation Bronchoscopy, fiber optic Bronchoscopy, Needle biopsy, CT guide... | 23,219 |
Study Objectives
Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in access t... | Inclusion Criteria:
* Individuals referred for cancer genetic counseling (e.g., by medical oncologist, primary care physician or self) in one of 4 oncology clinics: Gibson Cancer Center in Lumberton, NC; Scotland Cancer Treatment Center in Laurinburg, NC; Johnston Cancer Center in Smithfield, NC; and Maria Parham Canc... | 32,020 |
Study Objectives
Symptoms such as diarrhoea and abdominal discomfort are common side effects of radiotherapy for tumours in the pelvis and usually occur within 2 weeks of starting treatment. Once the course of radiotherapy has been completed these symptoms usually subside, but in some patients they may continue and som... | Inclusion Criteria:
* Any patient with gynaecological, bladder or rectal malignancy about to embark ona 5-6 week course of radical radiotherapy to the pelvis who is able to give informed consent
Exclusion Criteria:
* Patients unable or unwilling to give informed consent
* Patients who have already started radiothera... | 18,104 |
Study Objectives
The purpose of this study is to learn how blood flows to tumors in patients treated with I-125 plaque brachytherapy for uveal melanoma.
Conditions: Uveal Melanoma
Location: United States
Study Design and Phases
Study Type: OBSERVATIONAL
| Inclusion Criteria:
* Adults age 18 and older with uveal melanomas involving the ciliary body and/or the choroid undergoing I-125 plaque brachytherapy.
Exclusion Criteria:
* Inability to give informed consent.
* Inability to maintain stable fixation for OCT imaging
* Significant renal disease, defined as a history o... | 13,398 |
Study Objectives
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Intervention / Treatment:
DRUG: MEDI-573, ... | Inclusion Criteria:
* Histologically-confirmed MBC not deemed amenable to curative surgery or curative radiation therapy
* Tumors are positive for ER, PgR, or both
* Tumors must be negative for HER2 (by FISH, CISH or IHC)
* Female gender and age ≥ 18 years at time of study entry
* Postmenopausal
* Karnofsky Performanc... | 22,293 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 5